- N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth Formula I.
- -
-
Page/Page column 25
(2021/04/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 13; 14
(2021/04/17)
-
- N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 17
(2021/04/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
A compound of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
- -
-
Page/Page column 6
(2021/09/11)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
- -
-
Page/Page column 14
(2021/09/11)
-
- PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV
-
The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
- -
-
Page/Page column 156
(2021/10/30)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
A pharmaceutical composition comprising the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is set forth. (Formula Ia), (Formula Ib), (Formula Ic), (Formula Id)
- -
-
Page/Page column 12
(2021/10/22)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.
- -
-
Page/Page column 19-20
(2021/04/10)
-
- QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):
- -
-
Page/Page column 23-24
(2020/05/28)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 36
(2020/05/29)
-
- PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
The compound and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
- -
-
Page/Page column 7
(2021/01/22)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 14
(2020/04/25)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 29-30
(2020/06/01)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 14-15
(2020/05/07)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
- -
-
Page/Page column 41
(2020/06/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I).
- -
-
Page/Page column 14
(2020/06/01)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 30
(2020/06/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
The compound (I) and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 6
(2020/08/22)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
The compounds depicted below, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth (Formulae I or II).
- -
-
Page/Page column 7
(2020/11/13)
-
- COMPOUNDS USEFUL AS KINASE INHIBITORS
-
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
- -
-
Paragraph 00264
(2017/07/14)
-
- Monocycle gyrase and topoisomerase IV inhibitor
-
The invention belongs to the technical field of medicines, and in particular relates to a gyrase and topoisomerase IV inhibitor compound of formula (I) as shown in the specification, and a pharmaceutically acceptable salt, an ester or stereoisomers thereo
- -
-
Paragraph 0406; 0410-0412
(2017/01/05)
-
- MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS
-
Compounds of formula (I):or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.
- -
-
Page/Page column 95-96
(2014/09/29)
-
- COMPOUNDS FOR THE TREATMENT OF HIV
-
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
- -
-
Page/Page column 253
(2013/03/26)
-
- Cage escape competes with geminate recombination during alkane hydroxylation by the diiron oxygenase AlkB
-
(Chemical Presented) AlkBstops the radical clock: Three structurally analogous radical-clock substrates with a large span in their rearrangement rates are hydroxylated by AlkB to afford similar amounts of rearranged (2) and unrearranged products (1). Such a result is in accord with radical rebound competing with cage escape of the geminate substrate radical. The results show that radical clocks can measure both the radical lifetime and the kinetics of cage escape.
- Austin, Rachel N.,Luddy, Kate,Erickson, Karla,Pender-Cudlip, Marilla,Bertrand, Erin,Deng, Dayi,Buzdygon, Ryan S.,Van Beilen, Jan B.,Groves, John T.
-
supporting information; experimental part
p. 5232 - 5234
(2009/04/04)
-
- The diagnostic substrate bicyclohexane reveals a radical mechanism for bacterial cytochrome P450 in whole cells
-
(Figure Presented) On home ground: The reaction mechanisms of bacterial alkane-oxidizing cytochrome P450s were determined in their native environment using a novel diagnostic substrate probe, bicyclohexane, in whole cells and cell-free extracts (see picture). Purified P450cam also oxidizes bicyclohexane. Clear evidence for a substrate-based radical with a lifetime of 75-250 ps was obtained.
- Austin, Rachel N.,Deng, Dayi,Jiang, Yongying,Luddy, Kate,Van Beilen, Jan B.,Ortiz De Montellano, Paul R.,Groves, John T.
-
p. 8192 - 8194
(2008/02/08)
-
- Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
-
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
- -
-
Page/Page column 25
(2008/06/13)
-
- Synthesis, Configuration, and Evaluation of Two Conformationally Restrained Analogues of Phenicyclidine
-
Brown oxidation of cis-bicyclohexan-3-ol afforded bicyclohexan-3-one in 98percent yield.Treatment of this ketone with either phenyllithium or phenylmagnesium bromide in ether at room temperature followed by solvolysis of the resulting alcoho
- Costa, Brian R. de,George, Clifford,Burke, Terrence R.,Rafferty, Michael F.,Contreras, Patricia C.,et al.
-
p. 1571 - 1575
(2007/10/02)
-